[go: up one dir, main page]

AR051954A1 - Agregados de superficie extendida en el tratamiento de condiciones patologicas de la piel - Google Patents

Agregados de superficie extendida en el tratamiento de condiciones patologicas de la piel

Info

Publication number
AR051954A1
AR051954A1 ARP050104734A ARP050104734A AR051954A1 AR 051954 A1 AR051954 A1 AR 051954A1 AR P050104734 A ARP050104734 A AR P050104734A AR P050104734 A ARP050104734 A AR P050104734A AR 051954 A1 AR051954 A1 AR 051954A1
Authority
AR
Argentina
Prior art keywords
component
skin
esas
treatment
amphipathic
Prior art date
Application number
ARP050104734A
Other languages
English (en)
Inventor
Matthias Rother
Gregor Cevc
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR051954(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idea Ag filed Critical Idea Ag
Publication of AR051954A1 publication Critical patent/AR051954A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La presente se refiere al uso de agregados de superficie extendida (ESAs) que comprenden al menos un primer componente amfipático, el cual es un componente básico productor de agregado, y al menos un segundo componente amfipático, el cual disminuye la sensibilidad del agregado a la tension física, incluyendo estrés creado por el paso impuesto de dichos ESAs a través de poros con un diámetro promedio de al menos un 50% menor al diámetro de poro promedio de ESAs antes de dicho paso, de modo que el cambio de diámetro promedio de ESA inducido por dicha tension física es disminuido en un 10% o más, comparado con el cambio de diámetro inducido por dicho estrés bajo un sistema de referencia que comprende solo el primer o solo el segundo componente agregado, en la fabricacion de una preparacion farmacéutica para tratamiento perdurable de condiciones patologicas en la piel de mamíferos, incluyendo irritacion de la piel, inflamacion de la piel y/o dano de la piel después de aplicacion topica, para modificar la pigmentacion de la piel y/o para el tratamiento de picazon a la piel. Reivindicacion 2: Uso, de acuerdo a la reivindicacion precedente, caracterizado porque dicho al menos segundo componente amfipático es un NSAID, tal como ketoprofeno, ibuprofeno, diclofenaco, indometacino, naproxeno o piroxicam. Reivindicacion 8: Uso, de acuerdo a cualquiera de las reivindicaciones precedentes, caracterizado porque dicho el primer componente amfipático es un fosfatidilcolino y el segundo o tercer componente es un NSAID, tal como ketoprofeno, diclofenaco, ibupofeno, indometacino, naproxeno, o piroxicam. Reivindicacion 15: Uso, de acuerdo a cualquiera de las reivindicaciones precedentes, caracterizado porque dichos ESAs comprenden un alcohol alifático menor, preferentemente n-propanol, isopropanol, 2-propanol, n-butanol, 2-butanol, 1,2-propanediol, 1,2-butanediol, o etanol como un agregado adicional o un componente desestabilizante de membranas.
ARP050104734A 2004-11-12 2005-11-11 Agregados de superficie extendida en el tratamiento de condiciones patologicas de la piel AR051954A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62754604P 2004-11-12 2004-11-12
US64272305P 2005-01-10 2005-01-10
US69922905P 2005-07-13 2005-07-13

Publications (1)

Publication Number Publication Date
AR051954A1 true AR051954A1 (es) 2007-02-21

Family

ID=36129998

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104734A AR051954A1 (es) 2004-11-12 2005-11-11 Agregados de superficie extendida en el tratamiento de condiciones patologicas de la piel

Country Status (8)

Country Link
US (1) US20080095722A1 (es)
EP (1) EP1811961A2 (es)
JP (1) JP2008519784A (es)
KR (1) KR20070086045A (es)
AR (1) AR051954A1 (es)
CA (1) CA2584475A1 (es)
TW (1) TW200626184A (es)
WO (1) WO2006050926A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
KR20130079645A (ko) 2005-07-18 2013-07-10 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
ES2660906T3 (es) 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
EP2254546A4 (en) * 2008-02-20 2014-07-09 Elc Man Llc TOPICAL COMPOSITIONS AND METHODS FOR LAUNDERING THE SKIN
DE112010003355T5 (de) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Veskuläre Formulierungen
GB2503844A (en) * 2011-03-21 2014-01-08 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
JP5797470B2 (ja) * 2011-06-13 2015-10-21 エスエス製薬株式会社 皮膚沈着色素排出促進剤
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
WO2015014965A1 (en) * 2013-07-31 2015-02-05 Pro Bono Bio International Trading Ltd Vesicles
PT3316857T (pt) 2015-06-30 2021-11-03 Sequessome Tech Holdings Limited Composições multifásicas
CN110198703A (zh) 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
CN109381702A (zh) * 2018-10-09 2019-02-26 卢坤 一种纳米载体及其外用制剂的制备和应用方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4369182A (en) * 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
IL64397A0 (en) * 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
EP0088046B1 (de) * 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
USRE33273E (en) * 1982-08-18 1990-07-24 Georgia Tech Research Corporation Materials having improved nonfouling characteristics and method of making same
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
GB8321913D0 (en) * 1983-08-15 1983-09-14 Acacia Chem Ltd Spray method
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
IN166447B (es) * 1985-11-27 1990-05-12 Ethicon Inc
DE3542773A1 (de) * 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
US4937182A (en) * 1985-12-19 1990-06-26 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
US5244678A (en) * 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
KR900007831B1 (ko) * 1986-11-28 1990-10-20 더 리포조옴 캄파니, 인코포레이티드 인지질 조성물
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US5238613A (en) * 1987-05-20 1993-08-24 Anderson David M Microporous materials
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4937078A (en) * 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
DE69008534T2 (de) * 1989-08-03 1994-08-18 Hisamitsu Pharmaceutical Co Hautcremezubereitung zur äusserlichen verwendung.
US5104661A (en) * 1989-08-14 1992-04-14 Technology Unlimited, Inc. Reverse loading of liposomes
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003122A1 (de) * 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
CA2109956C (en) * 1991-06-10 1998-05-05 Dieter Beutner Nitroglycerine plaster and process for making it
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
EP0608320B1 (en) * 1991-10-16 1998-01-28 Richardson-Vicks, Inc. Enhanced skin penetration system for improved topical delivery of drugs
EG20380A (en) * 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
US5985860A (en) * 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
ES2107668T3 (es) * 1992-07-08 1997-12-01 Dianorm G Maierhofer Gmbh Liposomas, procedimiento para su preparacion y su uso en la elaboracion de un medicamento.
EP0652774B1 (en) * 1992-07-28 1997-05-07 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
US5958772A (en) * 1998-12-03 1999-09-28 Isis Pharmaceuticals Inc. Antisense inhibition of cellular inhibitor of apoptosis-1 expression
DE69328545T2 (de) * 1993-03-24 2001-07-05 Collaborative Laboratories Inc., East Setauket Kosmetisches Verabreichungssystem für Salizylsäure und Verfahren zur Herstellung desselben
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
FR2714601B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition dépigmentante pour le traitement simultané des couches superficielles et profondes, son utilisation.
US5716526A (en) * 1994-01-14 1998-02-10 The Liposome Company, Inc. Method of separating materials from liposomes or lipid complexes
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
ATE223202T1 (de) * 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
AU3559695A (en) * 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
IT1270678B (it) * 1994-10-20 1997-05-07 Bayer Ag Liposomi al chetoprofen
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
IT1275955B1 (it) * 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
DE19512181C2 (de) * 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
DE19518221A1 (de) * 1995-05-10 1996-11-14 Schering Ag Verwendung nichtsteroidaler Entzündungshemmer zur Verbesserung der physiologischen Verträglichkeit partikulärer pharmazeutischer Zubereitungen
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
FR2756734B1 (fr) * 1996-12-06 1999-01-15 Oreal Utilisation de paracetamol comme agent depigmentant
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
WO1998051281A1 (en) * 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
IT1298214B1 (it) * 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.
US6193996B1 (en) * 1998-04-02 2001-02-27 3M Innovative Properties Company Device for the transdermal delivery of diclofenac
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
EP1143958B8 (en) * 1998-09-03 2007-05-23 Loma Linda University Medical Center Pharmaceutical composition and use of rnsaid for treating inflammation
HRP20010309B1 (en) * 1998-12-23 2005-06-30 Idea Ag Improved formulation for topical non-invasive application in vivo
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6362227B1 (en) * 1999-03-02 2002-03-26 Sepracor, Inc. Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen
EP1191977A1 (en) * 1999-06-18 2002-04-03 Powerlung Inc Pulmonary exercise device
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
JP2001036949A (ja) * 1999-07-19 2001-02-09 Hitachi Ltd 無線通信方法および無線通信システム
US6685928B2 (en) * 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
US6248353B1 (en) * 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US6645520B2 (en) * 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1116485A3 (de) * 2000-01-10 2002-01-16 Gerhard Dr. Gergely Instant-Granulat und Verfahren zu seiner Herstellung
US20020119188A1 (en) * 2000-02-08 2002-08-29 Susan Niemiec Method of manufacturing liposomes
CN1211164C (zh) * 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
US20020037877A1 (en) * 2000-07-26 2002-03-28 Alcon Universal Ltd. Pharmaceutical suspension compositions lacking a polymeric suspending agent
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
KR20030079784A (ko) * 2002-04-04 2003-10-10 마츠시타 덴끼 산교 가부시키가이샤 냉동 사이클 장치와, 그것을 구비하는 공기 조화기,냉장고, 온수 공급기 및 극저온 냉동 장치
PT1551370E (pt) * 2002-10-11 2008-02-07 Idea Ag Agregado com capacidade de deformação aumentada, que compreende pelo menos três anfipáticos, para o transporte melhorado através de barreiras semi-permeáveis e para a aplicação de fármaco não invasiva in vivo, especialmente através da pele
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
JP2008519784A (ja) 2008-06-12
WO2006050926A2 (en) 2006-05-18
WO2006050926A3 (en) 2006-10-12
EP1811961A2 (en) 2007-08-01
CA2584475A1 (en) 2006-05-18
US20080095722A1 (en) 2008-04-24
KR20070086045A (ko) 2007-08-27
TW200626184A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
AR051954A1 (es) Agregados de superficie extendida en el tratamiento de condiciones patologicas de la piel
Sun et al. Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel
AR064659A1 (es) Nanoemulsion
ES2559516T3 (es) Pulverizador nasal
Hu et al. Neuroprotective effects of Kukoamine A on neurotoxin-induced Parkinson's model through apoptosis inhibition and autophagy enhancement
CL2009001490A1 (es) Sistema de suministro intrauterino que comprende un progestageno o una droga con actividad progestagenica y una sustancia terapeuticamente activa seleccionada de naproxeno, indometacina, ibuprofeno, acido mefenamico o flurbiprofeno, con la capacidad de evitar o suprimir el sangrado anormal y/o irregular.
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2011002755A1 (es) Composicion farmaceutica topica que comprende particulas de fosfato de calcio nanoporosas, esfericas, donde al menos 90% o mas de las particulas tienen un diametro promedio de 2 micrometros o menos y estan enlazadas a un agente farmacologicamente activo.
CL2013003227A1 (es) “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct
CL2009000902A1 (es) Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
CL2011002634A1 (es) Disolucion acuosa sin alcohol etilico que comprende propanolol o una sal farmaceuticamente aceptable del mismo, un edulcorante tipo no azucarado y menos del 0,01 % (p/v) de un agente conservante; procedimiento de preparacion; uso de la disolucion en el tratamiento de hemangiomas.
AR069704A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
CL2011000244A1 (es) Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.
AR055552A1 (es) Preparacion topica refrescante para parches y metodos para utilizar la misma
Güngör et al. Effect of penetration enhancers on in vitro percutaneous penetration of nimesulide through rat skin
AR071334A1 (es) Gel de quitosano para aplicaciones dermatologicas, proceso de obtencion y uso del mismo
AR097997A1 (es) Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
de Araujo et al. Bioadhesive films containing benzocaine: correlation between in vitro permeation and in vivo local anesthetic effect
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
AR088051A1 (es) Preparacion de liberacion prolongada de feromona sexual del tipo de dispersion en agua
Bernardes et al. Preclinical study of methotrexate-based hydrogels versus surfactant based liquid crystal systems on psoriasis treatment
Haraguchi et al. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor γ-dependent mechanism

Legal Events

Date Code Title Description
FA Abandonment or withdrawal